Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Indiana Healthcare Today.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on June 12, 2025
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
GlobeNewswire
·
June 12, 2025
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of …
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
GlobeNewswire
·
June 12, 2025
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – 93% (41/44) and 89% (24/27) CRc observed in NPM1-m and …
NewGen Announces Planned US$45 Million Strategic Investment in UAE Real Estate Market
GlobeNewswire
·
June 12, 2025
The Company’s initial investment into the Emirate of Ras Al Khaimah comes ahead of major tourism and infrastructure developments NewGen plans to diversify via additional real estate investments in Abu Dhabi pending potential transactions to provide …
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
GlobeNewswire
·
June 12, 2025
CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in …
Spring Bio Solution lance NCE Grid pour décoder les dépôts Para IV et les opportunités de premier déposant
GlobeNewswire
·
June 12, 2025
SOMERSET, New Jersey, 12 juin 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, l’un des leaders mondiaux de l’approvisionnement en comparateurs et en matériel pour essais cliniques, a lancé NCE Grid, une plateforme d’informations NCE-1 gratuite. Conçue pour …
スプリング・バイオ・ソリューション (Spring Bio Solution) 、パラグラフIV証明書を伴う申請 (Para IV Filing) およびファースト・トゥ・ファイル機会を解析するNCEグリッド (NCE Grid) を発表
GlobeNewswire
·
June 12, 2025
ニュージャージー州サマセット発, June 12, 2025 (GLOBE NEWSWIRE) -- コンパレータ調達および治験薬供給のグローバルリーダーであるスプリング・バイオ・ソリューションは、世界初の無料NCE-1インテリジェンス・プラットフォームであり、パラグラフIVおよびNCE-1の機会をリアルタイムで解析・集約・可視化することを目的として構築されたNCEグリッドを発表した。 これまで、NCE独占期間の満了およびパラグラフIV …
Spring Bio Solution 推出 NCE Grid，用于分析 Para IV 申请和“首先申请”机会
GlobeNewswire
·
June 12, 2025
萨默塞特，新泽西州, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution 是对照药采购和临床试验用品领域的全球领导者，近日推出了 NCE Grid，这是全球首个免费的 NCE-1（新化学实体批准日期满48个月后的第一天，通常被称为“首仿日”）情报平台，用于实时分析及实现 Para IV（第IV段声明专利挑战） 和 NCE-1 机会的集中化和可视化。 在这之前，追踪 NCE 独占期到期情况和 Para IV …
Spring Bio Solution เปิดตัว NCE Grid เพื่อถอดรหัสการยื่นเอกสาร Para IV และโอกาสในการยื่นคำขอครั้งแรก
GlobeNewswire
·
June 12, 2025
ซอเมอร์เซ็ต นิวเจอร์ซีย์, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution ผู้นำระดับโลกในด้านการจัดหาตัวเปรียบเทียบและอุปกรณ์การทดลองทางคลินิก ได้เปิดตัว NCE Grid แพลตฟอร์มปัญญาประดิษฐ์ NCE-1 ฟรีแห่งแรกของโลกที่สร้างขึ้นเพื่อถอดรหัส การรวมข้อมูล …
Spring Bio Solution 推出 NCE Grid，用於分析 Para IV 申請和「首先申請」機會
GlobeNewswire
·
June 12, 2025
薩默塞特，新澤西州, June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution 是對照藥採購和臨床試驗用品領域的全球領導者，近日推出了 NCE Grid，這是全球首個免費的 NCE-1 情報平台，用於即時分析及實現 Para IV 和 NCE-1 機會的集中化和可視化。 到目前為止，追蹤 NCE 專有權到期情況和 Paragraph IV 申請一直是分散且繁瑣的人手程序，缺乏集中式解決方案。 …
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire
·
June 12, 2025
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse …
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
June 12, 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data …
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström…
GlobeNewswire
·
June 12, 2025
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces …
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning
GlobeNewswire
·
June 12, 2025
EXTON, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the publication of pivotal clinical trial results in the American …
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
GlobeNewswire
·
June 12, 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy- …
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
GlobeNewswire
·
June 12, 2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
GlobeNewswire
·
June 12, 2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement …
Gavin Gassen, M.D. Brings His Expertise to ENT and Allergy Associates’ Poughkeepsie Office
GlobeNewswire
·
June 12, 2025
Tarrytown, New York, June 12, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the country, is proud to welcome Gavin M. Gassen, M.D., a board-certified Otolaryngologist and …
Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR
GlobeNewswire
·
June 12, 2025
Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving effects First-in-class novel biologic …
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire
·
June 12, 2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to …
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
GlobeNewswire
·
June 12, 2025
COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its …